Did you mean antibody arsenic?
Displaying drugs 576 - 600 of 651 in total
Indium In-111 imciromab pentetate
Indium In-111 imciromab pentetate is a mouse monoclonal antibody labelled with the radioisotope Indium-111 which was used for cardiac imaging under the trade name Myoscint, but was withdrawn in 1993.
Withdrawn
Matched Description: … Indium In-111 imciromab pentetate is a mouse monoclonal antibody labelled with the radioisotope Indium …
Tucotuzumab celmoleukin
Tucotuzumab celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment).
Investigational
Matched Description: … celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody …
Andecaliximab
Andecaliximab is a monoclonal antibody directed against matrix metallopeptidase 9 (MMP9). Andecaliximab is under investigation in clinical trial NCT03631836 (Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma).
Investigational
Matched Description: … Andecaliximab is a monoclonal antibody directed against matrix metallopeptidase 9 (MMP9). …
Cixutumumab
Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate.
Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of...
Investigational
Matched Description: … Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like …
Nivatrotamab
Nivatrotamab is under investigation in clinical trial NCT03860207 (Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3f8-bsab) in Patients With Relapsed/refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers).
Investigational
Matched Description: … investigation in clinical trial NCT03860207 (Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody …
CoviGlobulin
CoviGlobulin, a rabbit polyclonal antibody, was specifically designed as a potential therapy for COVID-19. Rabbit polyclonal antibodies are derived from the rabbit, a common animal host for polyclonal production. The antibodies themselves are produced in response to an immunogen and derived from antibody-producing plasma cells that were once B-cell clones....
Investigational
Matched Description: … CoviGlobulin, a rabbit polyclonal antibody, was specifically designed as a potential therapy for COVID ... The antibodies themselves are produced in response to an immunogen and derived from antibody-producing …
HGS-TR2J
HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies. It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.
Investigational
Matched Description: … HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced …
XmAb 2513
XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. It has been investigated for the treatment of hodgkin’s lymphoma.
Investigational
Matched Description: … XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the …
Bertilimumab
Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development. It is developed by MedImmune for the treatment of Allergic Rhinitis.
Investigational
Matched Description: … Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic …
Depatuxizumab mafodotin
Depatuxizumab/Denintuzumab mafodotin has been used in trials studying the treatment of Lymphoma, Gliosarcoma, Glioblastoma, Malignant Glioma, Squamous Cell Tumors, and Glioblastoma Multiforme.
Investigational
IMC-1C11
IMC-1C11 is an anti-angiogenesis agent. It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation. IMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma.
Investigational
Matched Description: … It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction …
Efzofitimod
Efzofitimod (ATYR1923) is a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody. It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states.
Investigational
Matched Description: … comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody …
AGS-16C3F
AGS 16C3F is an intravenously administered, anti-ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) antibody-drug conjugate. AGS-16C3F is under investigation in clinical trial NCT02639182 (A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma).
Investigational
Matched Description: … 16C3F is an intravenously administered, anti-ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) antibody-drug …
PRA023
PRA023 is a humanized monoclonal antibody directed to vascular endothelial growth inhibitor, also known as tumour necrosis factor (TNF)-like ligand 1A (TL1A) and TNF superfamily member 15. It is being investigated for ulcerative colitis.
Investigational
Matched Description: … PRA023 is a humanized monoclonal antibody directed to vascular endothelial growth inhibitor, also known …
CT-011
CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies. It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities.
Investigational
Matched Description: … CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients …
Theralizumab
Theralizumab is a humanized anti-CD28 monoclonal antibody designed for treating autoimmune diseases and cancer. After the first human trial, it was withdrawn due to severe toxicity (likely due to lymphopenia and human cytokine release).[A216527,A216532]
Investigational
Matched Description: … Theralizumab is a humanized anti-CD28 monoclonal antibody designed for treating autoimmune diseases and …
Zalutumumab
Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). Zalutumumab has been investigated for the treatment of Squamous Cell Cancer and Head and Neck Cancer.
Investigational
Matched Description: … Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal …
RAV12
RAV12 is investigated for use/treatment in solid tumors. RAV12 is a solid. RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells.
Investigational
Matched Description: … RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric …
RI 624
RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain. RI 624 is being developed by Rinat and is currently in Phase I clinical trials.
Investigational
Matched Description: … RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator …
Dacetuzumab
Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse. It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells.
Investigational
Matched Description: … It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells. …
RO7296682
RO7296682 is a monoclonal antibody against CD25 (IL-2R alpha) expressed on tumour-infiltrating regulatory T (Treg) cells. RO7296682 is under investigation in clinical trial NCT04642365 (A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.).
Investigational
Matched Description: … RO7296682 is a monoclonal antibody against CD25 (IL-2R alpha) expressed on tumour-infiltrating regulatory …
SCIB1
SCIB1 is an investigational cancer vaccine being developed by Scancell Ltd. It is being investigated for the treatment of melanoma. It consists of plasmid DNA molecules that express a modified antibody in human cells, working to stimulate the patient's T cells to have a stronger reaction against melanoma cells.
Investigational
Matched Description: … It consists of plasmid DNA molecules that express a modified antibody in human cells, working to stimulate …
Matuzumab
Matuzumab (formerly known as the experimental drug, EMD 72000) is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival.
Investigational
Matched Description: … Matuzumab (formerly known as the experimental drug, EMD 72000) is a humanized monoclonal antibody used …
CYT007-TNFQb
CYT007-TNFQb is an active immunization therapy that aims at
providing a novel treatment to people suffering from RA or psoriasis. The vaccine should allow for administration of low
amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules.
Investigational
Talacotuzumab
Talacotuzumab is an IgG1 monoclonal antibody directed toward the IL3 receptor α–subunit, also known as CD123. It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission).
Investigational
Matched Description: … Talacotuzumab is an IgG1 monoclonal antibody directed toward the IL3 receptor α–subunit, also known as …
Displaying drugs 576 - 600 of 651 in total